

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-84 (canceled)

Claim 85 (new) A liquid lansoprazole formulation comprising lansoprazole and an excipient system, wherein:

(a) the concentration of lansoprazole in the formulation ranges from about 0.3 mg/mL to about 50 mg/mL;

(b) the excipient system comprises either a single excipient, or a combination of two to four compositionally distinct excipients, wherein each excipient is selected from the group of excipient categories consisting of: a hydrotrope, a preservative, a pharmaceutically acceptable salt, a surfactant, a base, a cyclodextrin, a viscosity modifier, an emulsifier, a solvent, a carrier, and a lubricant; and

(c) the formulation may be administered parenterally to a mammal in need thereof.

Claim 86 (new) The formulation of claim 85, comprising a two-excipient system in which the concentration of each excipient in the formulation ranges from about 0.4 mg/mL to about 60 mg/mL and total excipient concentration in the formulation ranges from about 0.8 mg/mL to about 120 mg/mL.

Claim 87 (new) The formulation of claim 86, further comprising a diluent and a preservative that acts as an antimicrobial agent.

Claim 88 (new) The formulation of claim 85, comprising lansoprazole and a single excipient.

Claim 89 (new) The formulation of claim 85, comprising lansoprazole in combination with a two-excipient system comprising either compositionally distinct first and second excipients

selected from the same excipient category, or compositionally distinct first and second excipients selected from different excipient categories.

Claim 90 (new) The formulation of claim 88, wherein the excipient is either a hydrotrope, a preservative, a pharmaceutically acceptable salt, a surfactant, a base, a cyclodextrin, a viscosity modifier, an emulsifier, a solvent, a carrier, or a lubricant.

Claim 91 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second emulsifiers, or an emulsifier in combination with: (i) a viscosity modifier, (ii) a carrier, (iii) a base, (iv) a solvent, or (v) a surfactant.

Claim 92 (new) The formulation of claim 89, wherein the excipient system comprises a preservative in combination with: (i) a carrier, (ii) a surfactant, (iii) a solvent, or (iv) a cyclodextrin.

Claim 93 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second cyclodextrins, or a cyclodextrin in combination with: (i) an emulsifier, (ii) a viscosity modifier, (iii) a carrier, (iv) a lubricant, (v) a surfactant, or (vi) a solvent.

Claim 94 (new) The formulation of claim 89, wherein the excipient system comprises a pharmaceutically acceptable calcium salt in combination with: (i) a carrier, (ii) a base, (iii) a solvent, or (iv) a surfactant.

Claim 95 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second surfactants, or a surfactant in combination with: (i) a carrier, (ii) a viscosity modifier, (iii) a base, (iv) a pharmaceutically acceptable salt other than a calcium salt, (v) a solvent, (vi) a lubricant, or (vii) a hydrotrope.

Claim 96 (new) The formulation of claim 89, wherein the excipient system comprises a hydrotrope in combination with: (i) a viscosity modifier, (ii) a carrier, (iii) a preservative, (iv) a base, (v) a solvent, or (vi) a cyclodextrin.

Claim 97 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second viscosity modifiers, or a viscosity modifier in combination with: (i) a carrier, (ii) a lubricant, or (iii) a solvent.

Claim 98 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second carriers, or a carrier in combination with: (i) a solvent, or (ii) a lubricant.

Claim 99 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second bases, or a base in combination with: (i) a preservative, (ii) a solvent, (iii) a carrier, (iv) a viscosity modifier, (v) a lubricant, or (vi) a cyclodextrin.

Claim 100 (new) The formulation of claim 89, wherein the excipient system comprises either compositionally distinct first and second solvents, or a solvent in combination with: (i) a salt, or (ii) a lubricant.

Claim 101 (new) The formulation of claim 89, wherein the excipient system comprises compositionally distinct first and second lubricants.

Claim 102 (new) The formulation of claim 88, wherein the excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil, polysorbate 20, polysorbate 80, poloxamers, deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin, lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

Claim 103 (new) The formulation of claim 89, wherein each excipient is selected from the group consisting of: sorbitol, mannitol, lactose, benzethonium chloride, chlorobutanol, methylparaben, methanol, ethanol, i-propanol, n-butanol, calcium chloride, magnesium chloride, calcium gluconate, calcium glubionate, calcium gluceptate, polyoxyethylated castor oil, polysorbate 20, polysorbate 80, poloxamers, deoxycholic acid and salts of deoxycholic acid, lysine, diethanolamine, gamma cyclodextrin, hydroxypropyl-beta-cyclodextrin, polyvinylpyrrolidone, glycerin, lecithin, sodium benzoate, sodium acetate, sodium tartrate, polyethylene glycol, starch, and propylene glycol.

Claim 104 (new) The formulation of claim 85, wherein:

- (a) the concentration of lansoprazole in the formulation is between about 4.0 mg/mL to 50 mg/mL; and
- (b) the excipient system is a four-excipient system comprising a surfactant, compositionally distinct first and second solvents, and an alcohol.

Claim 105 (new) The formulation of claim 104, wherein the surfactant is a polysorbate, the first and second solvents are polyethylene glycols, and the alcohol is methanol, ethanol, i-propanol or n-butanol.

Claim 106 (new) The formulation of claim 105, wherein the surfactant is polysorbate 80, the first or second solvent is PEG-300, and the alcohol is ethanol.

Claim 107 (new) The formulation of claim 85, wherein:

- (a) the concentration of lansoprazole in the formulation is between about 0.4 mg/mL to about 40 mg/mL; and
- (b) the excipient system is a three-excipient system comprising a surfactant and compositionally distinct first and second solvents.

Claim 108 (new) The formulation of claim 107, wherein the surfactant is a polysorbate and the first and second solvents are compositionally distinct polyethylene glycols.

Claim 109 (new) The formulation of claim 108, wherein the surfactant is polysorbate 80 and the first or second solvent is PEG-300.